Nanomedicines for Alzheimer's disease: Therapies based on pathological mechanisms
Authors:
Open Access
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder worldwide. Because of the complex pathogenesis of AD and the unique location of AD lesions, effective clinical treatment strategies for this disease remain elusive. However, the development of nanotechnology has allowed a new era of AD treatment to emerge. AD nanomedicines are products of interdisciplinary research that enable high precision and targeted delivery. Additionally, they can specifically regulate various pathogenic factors. This review focuses on nanomedicines based on the pathological mechanisms of AD that can target AD lesions. We also discuss the precise regulatory effects of nanomedicines (including the nanomaterials themselves) on pathogenic proteins, neuroinflammatory molecules, and other pathogenic factors. We summarize the clinical trials that have examined new AD drugs, highlighting the development of new nanomedicines and the progress in their clinical translation. Nanotechnology‐based AD treatment is a nascent field, and a complete cure is distant at present; therefore, we also elaborate on the shortcomings of current AD nanomedicines. Finally, we discuss the prospects to guide the future development of AD nanomedicines.Keywords
This publication has 156 references indexed in Scilit:
- Curcumin in Alzheimer’s disease: Can we think to new strategies and perspectives for this molecule?Pharmacological Research, 2017
- Redox-responsive theranostic nanoplatforms based on inorganic nanomaterialsJournal of Controlled Release, 2017
- High throughput approaches for controlled stem cell differentiationActa Biomaterialia, 2016
- Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti‐tau antibody AT8Proteins: Structure, Function, and Bioinformatics, 2016
- Copper mediated neurological disorder: Visions into amyotrophic lateral sclerosis, Alzheimer and Menkes diseaseJournal of Trace Elements in Medicine and Biology, 2015
- Development and Applications of CRISPR-Cas9 for Genome EngineeringCell, 2014
- Using Graphene Oxide High Near‐Infrared Absorbance for Photothermal Treatment of Alzheimer's DiseaseAdvanced Materials, 2012
- Targeting Mitochondria with Organelle‐Specific Compounds: Strategies and ApplicationsChemBioChem, 2009
- Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: Involvement of endoplasmic reticulum calcium release in oligomer-induced cell deathNeuroscience, 2008
- A novel peptide defined through phage display for therapeutic protein and vector neuronal targetingNeurobiology of Disease, 2005